Skip to Content
You are currently on the new version of our website. Access the old version .
  • 114 days
    Submission to First Decision
  • 7 days
    Acceptance to Publication

Journal of the Oman Medical Association

Journal of the Oman Medical Association (JOMA) is an international, peer-reviewed, open access journal on healthcare, clinical medicine, and other scientific areas related to medicine and surgery, published semiannually online. It is the official journal of the Oman Medical Association (OMA). Association members receive discounts.
  • Open Access— free for readers and authors (diamond open access), with article processing charges (APC) paid by the Oman Medical Association. OMA members receive a discount. 
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 113.2 days after submission; acceptance to publication is undertaken in 6.6 days (median values for papers published in this journal in the first half of 2026).
  • Recognition of Reviewers: Reviewers whose reports are timely and of high quality receive an APC discount voucher for a future publication in an MDPI journal. Become a reviewer.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (57)

  • Case Report
  • Open Access

Suppressed thyroid-stimulating hormone (TSH) in older adults carries cardiovascular and skeletal risk, and the steps needed to evaluate it are well established. We describe an 83-year-old woman with type 2 diabetes, hypertension, coronary artery disease after bypass grafting, and atrial fibrillation, living in a rural district and educated to primary-school level, in whom these steps were not taken for several years. Between 2019 and 2026, TSH was 0.1 mIU/L or lower on 10 of 11 measurements. Free thyroxine was always within its reference interval; free triiodothyronine (FT3) was normal on most occasions, exceeded the upper reference limit once in 2022, and was not measured at the index visit. Thiamazole had been prescribed briefly in 2019 but remained on her medication list, and at cardiology and ophthalmology visits the low TSH was not pursued because the record showed antithyroid treatment. At a family medicine visit for renewal of her medication reports, review of her past records, a structured medication interview, and national dispensing records showed no continuing antithyroid treatment. Comprehensive geriatric assessment identified malnutrition risk and iron-deficiency anemia as additional explanations for her weight loss. TSH receptor antibody testing, thyroid imaging, and endocrinology referral were recommended. After the risks had been explained, she declined travel and further investigation, and monitoring was arranged locally. The cause of TSH suppression remains unknown, and T3 toxicosis cannot be excluded. The case does not describe a new disorder. It shows how a known diagnostic approach can go unused when care is divided among specialties and the medication list is accepted without checking. It supports reviewing the past record, confirming whether and at what dose a recorded drug is actually taken, informing the patient, and continuing follow-up with explicit criteria for renewed referral when investigation is declined.

J. Oman Med. Assoc.

11 November 2026

Thyroid function tests and clinical events, 2019–2026. (A) TSH on a logarithmic scale; the shaded band shows the reference interval of the index laboratory and the dashed line marks the 0.1 mIU/L threshold for grade 2 suppression. The November 2019 value reported as <0.01 mIU/L is plotted at 0.01. (B) FT4 and (C) FT3; shaded bands show the reference intervals used by most of the laboratories (the index laboratory used 0.72–1.89 ng/dL for FT4). The FT3 value above the upper limit in November 2022 is shown in orange; FT3 was not measured at the index visit. (D) Documented thiamazole use, emergency visits, the emergency electrocardiogram showing atrial fibrillation (already listed in the history), and family medicine contacts. FT3—free triiodothyronine; FT4—free thyroxine; TSH—thyroid-stimulating hormone.
  • Article
  • Open Access

Virulence Determinants of Urinary Pseudomonas aeruginosa Clinical Isolates: A Phenotypic and Genotypic Study

  • Mohammed Irmayyidh Mutar,
  • Velayuthaprabhu Shanmugam and
  • Manoj Mani
  • + 2 authors

This study aimed to characterize antimicrobial resistance, biofilm formation, and phenotypic and genotypic virulence-associated traits in urinary P. aeruginosa isolates in Iraq. Methods: Twenty P. aeruginosa isolates recovered from 100 urine samples from patients with urinary tract infections at Al-Ramadi Teaching Hospital, Anbar, Iraq, were characterized using conventional biochemical tests and the VITEK® 2 automated system. The expected 16S rRNA gene amplicon was assessed in all isolates; sequencing and phylogenetic analysis were performed on four selected isolates. Biofilm formation was assessed using the crystal violet microtiter plate, tube adherence, and Congo red agar methods. Antimicrobial susceptibility was tested by Kirby–Bauer disk diffusion using CLSI M100, 35th edition (2025), and the multiple antibiotic resistance (MAR) index was calculated using six antimicrobial agents. Phenotypic assays assessed capsule-associated extracellular polysaccharide production, protease, lecithinase, coagulase, hemolytic and pyocin activity, pigment production, and adhesion to human uroepithelial cells. PCR was used to detect algD, lasR, oprD, and mexB. Separately, a retrospective review of 188 urine-culture records from 2025 identified 131 culture-positive specimens. Results: All 20 isolates were identified as P. aeruginosa and met the study’s MDR criterion. MAR indices ranged from 0.33 to 1.00. All isolates formed biofilms; by the crystal violet assay, four (20%) were strong producers and 16 (80%) were moderate producers. Capsule-associated extracellular polysaccharide production, protease activity, β-hemolysis, and pyocin activity were detected in all 20 isolates. Pyocyanin was detected in 16 (80%) isolates, and pyoverdine was detected in seven (35%) isolates. Adhesion indices ranged from 4.3 to 19.5 bacteria per cell, with 11 (55%) isolates classified as high-adherence. PCR detected all four target regions in all isolates, although target detection alone does not establish gene expression or function. In the separate retrospective survey, E. coli was the most frequently reported organism (27.5%), and P. aeruginosa accounted for 7.6% of positive cultures. Conclusions: These findings support local resistance surveillance, susceptibility-guided treatment, and infection-control measures. Larger studies linking molecular, phenotypic, and patient-level outcomes are needed.

J. Oman Med. Assoc.

10 November 2026

Phylogenetic relationships among four selected clinical isolates labelled S1, S4, S6, and S14 in the sequencing dataset and reference sequences obtained from GenBank. The tree was constructed using the Neighbor-Joining method with 1000 bootstrap replicates. Sequence-based phylogenetic analysis was performed on this selected subset; all 20 isolates were assessed by 16S rRNA gene PCR.
  • Review
  • Open Access

Ferroptosis is an iron-dependent form of regulated cell death increasingly implicated in neurological disease and injury. Although neuronal ferroptosis has received substantial attention, the contribution of microglia to neuronal ferroptotic susceptibility remains less clearly defined. This review examines how microglia may regulate neuronal responses to ferroptotic stress through iron handling, inflammatory and redox signalling, and extracellular vesicle-mediated communication. Evidence from intracerebral haemorrhage, subarachnoid haemorrhage, Parkinson’s disease, sepsis-associated encephalopathy, and other neurological contexts is evaluated with particular attention to experimental models, cellular specificity, and ferroptosis-related endpoints. Microglial regulation of neuronal iron homeostasis and inflammatory signalling is supported by several mechanistic studies, while microglia-derived extracellular vesicles provide an additional route through which iron and regulatory molecules may be delivered. However, evidence remains heterogeneous, and ferroptosis occurring within microglia themselves must be distinguished from neuronal ferroptosis. Important uncertainties include whether microglia directly transfer iron to neurons, whether microglia-specific manipulation can alter neuronal ferroptosis in vivo, and how consistently ferroptosis-associated endpoints distinguish ferroptosis from other forms of neuronal injury. Therapeutically, clinical studies of non-selective brain iron chelation caution against indiscriminate reduction in brain iron. Cell- and pathway-selective modulation of microglial iron handling or microglia–neuron signalling therefore represents a potential therapeutic direction that requires further validation.

J. Oman Med. Assoc.

10 November 2026

Conceptual model of microglial regulation of neuronal ferroptotic susceptibility. Microglial activation can alter neuronal ferroptotic susceptibility through changes in iron handling, redox and inflammatory signalling, and extracellular vesicle (EV) cargo. EVs represent a communication route rather than a separate mechanism and may carry pro-ferroptotic or protective cargo. Direct transfer of iron from microglia to neurons has not been demonstrated. Microglial ferroptotic stress is shown separately because it may cause secondary neuronal injury without establishing neuronal ferroptosis. Solid arrows indicate established or causal relationships, dashed arrows associative relationships, and dotted arrows proposed relationships.
  • Review
  • Open Access

Breast Cancer Detection and Treatment in Five East African Countries: Challenges, Advances, and Future Directions

  • Mussa Yussuf Khamis,
  • Abdallah Iddy Chaurembo and
  • Mohamed Zahir Alimohamed
  • + 2 authors

This narrative review examines breast cancer detection and treatment in Tanzania, Kenya, Uganda, Rwanda, and Ethiopia, where late-stage diagnosis and delays in care remain major public health concerns. Although reported incidence is lower than in many high-income settings, mortality relative to incidence remains high. We synthesize evidence on risk factors, early detection, diagnostic pathways, treatment access, health-system barriers, policy responses, and emerging priorities. Studies from these settings identify limited diagnostic capacity, workforce shortages, referral delays, financial barriers, and uneven oncology services as important obstacles to timely care. Germline BRCA1/2 testing may inform risk assessment and selected treatment decisions, while assessment of ER, PR, and HER2 informs systemic therapy. Consistent with WHO guidance, strengthening timely evaluation and referral of symptomatic women is a priority where organized, quality-assured population screening and downstream services are not yet feasible. Patient navigation, improved pathology and treatment capacity, financial protection, and context-appropriate precision oncology may strengthen care. Better outcomes will require investment across the continuum from symptom recognition through diagnosis, treatment, and follow-up.

J. Oman Med. Assoc.

10 November 2026

Breast cancer care pathway, common points of delay, and patient-navigation interventions in the five countries reviewed. Navigation may support referral, diagnostic completion, communication of results, treatment initiation, and follow-up. Supportive and palliative care can be required throughout the pathway. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Featured Articles of Last Quarter

Schematic representation of the HPV genome and the functions of its encoded proteins.

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
J. Oman Med. Assoc. - ISSN 2813-8759